|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0010583,
umls-concept:C0013089,
umls-concept:C0013216,
umls-concept:C0016360,
umls-concept:C0144576,
umls-concept:C0205197,
umls-concept:C0600558,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1521733,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1956267,
umls-concept:C2911692
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2004-6-15
|
|
pubmed:abstractText |
The goal of this study was to examine the feasibility of developing a multigene predictor of pathologic complete response (pCR) to sequential weekly paclitaxel and fluorouracil + doxorubicin + cyclophosphamide (T/FAC) neoadjuvant chemotherapy regimen for breast cancer.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:ArunBB,
pubmed-author:AyersMM,
pubmed-author:BooserDD,
pubmed-author:ClarkEE,
pubmed-author:DamokoshA IAI,
pubmed-author:HessKK,
pubmed-author:HortobagyiG NGN,
pubmed-author:IbrahimNN,
pubmed-author:LecockeMM,
pubmed-author:MetivierJJ,
pubmed-author:PusztaiLL,
pubmed-author:RossJJ,
pubmed-author:RoyceMM,
pubmed-author:SneigeNN,
pubmed-author:StecJJ,
pubmed-author:SymmansW FWF,
pubmed-author:ValeroVV,
pubmed-author:WhitmanGG
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2284-93
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:15136595-Adult,
pubmed-meshheading:15136595-Aged,
pubmed-meshheading:15136595-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15136595-Breast Neoplasms,
pubmed-meshheading:15136595-Chemotherapy, Adjuvant,
pubmed-meshheading:15136595-Cyclophosphamide,
pubmed-meshheading:15136595-Doxorubicin,
pubmed-meshheading:15136595-Feasibility Studies,
pubmed-meshheading:15136595-Fluorouracil,
pubmed-meshheading:15136595-Gene Expression Profiling,
pubmed-meshheading:15136595-Humans,
pubmed-meshheading:15136595-Middle Aged,
pubmed-meshheading:15136595-Neoadjuvant Therapy,
pubmed-meshheading:15136595-Paclitaxel,
pubmed-meshheading:15136595-Prognosis,
pubmed-meshheading:15136595-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
|
|
pubmed:affiliation |
Millennium Pharmaceuticals Inc, Cambridge, MA, USA.
|
|
pubmed:publicationType |
Journal Article
|
